Can anyone explain why some analysts recommend companies in the biopharmacy sector as a "buy" even though they have high R&amp;D costs and no real profit?

I followed three companies and I see the same story. The only positive number is income, and only in one case does it cover expenses after net borrowing. For the next four in a row, the net income the net income is below zero. 

Why are these companies a buy?


Question: Registration: Username and password or email and password
Answer: For me personally it's about giving my complete details before I'm even a member. I'd rather just sign up with email/pw and then later figure out how I will fill out my profile, as me or a more obscurely titled me. Example: for Facebook I use my full name but on here I've abbreviated my last name. 

I think opting for email/pw will give you a higher influx of sign-ups because it requires less thinking. 90% of all apps/startups/sites I apply for are email/pw sign-ups, or social (fb/twitter) sign-ups.

But that's just personal and not backed up by any study or anything...